Impaired mitochondrial function is a hallmark of aging and a number of age-related diseases. Mitochondrial dysfunction results from cumulative damage to mitochondrial DNA (mtDNA), which is the primary source of mitochondrial protein and energy production. mtDNA mutations can lead to a decrease in mitochondrial electron transport chain (ETC) efficiency and an increase in reactive oxygen species (ROS) production, which can further exacerbate mitochondrial dysfunction.

In recent years, mitochondrial DNA (mtDNA) has emerged as a promising biomarker for aging and age-related diseases. mtDNA mutagenesis is highly specific to aging due to its non-repairable nature. The accumulation of mtDNA mutations is associated with various age-related conditions, including cardiovascular disease, diabetes, neurodegenerative diseases, and cancers.

The main objective of this review is to provide an overview of current knowledge regarding the role of mtDNA in aging and age-related diseases. We will discuss the mechanisms by which mtDNA mutagenesis contributes to aging, the potential therapeutic strategies for mtDNA-related diseases, and the future perspectives for mtDNA research in the field of aging and age-related disorders.
JMJD3 plays an important role during the transition of ESCs and MSCs into specialized cells or the reprogramming of somatic cells to iPSCs [11, 30]. JMJD3 has been found to enhance self-renewal ability and reduce the differentiation capacity of pluripotent and multipotent stem cells [12, 31, 32]. In this review, we will focus on the recent advances of JMJD3 function in stem cell fate.

Structure and function of JMJD3

There are at least 6 families of histone demethylases. KDM4B (JMJD2B) and KDM6B (JMJD3) are two important histone demethylases [35–37]. Human JMJD3 or KDM6B (lysine-specific demethylase 6B) gene is located at 17p13.1 and encodes a polypeptide that contains 1682 amino acids with an average molecular weight of 176,632 Da [10, 38]. JMJD3 belongs to a subfamily of the UTX/UTY JmjC-domain protein [12]. UTX1 (KDM6A) and JMJD3 are the KDM6 family members that demethylate H3K27me3 [39, 40]. JMJD3 contains a Jumonji C (JmjC) domain (demethylates histones) and a C-terminal segment that is embedded with a GATA-like (GATAL) domain. The KDM6A protein has a catalytic JmjC domain at the C terminus and six tetratricopeptide repeat (TPR) domains at the N terminus [41, 42]. The KDM6A protein has a catalytic JmjC domain at the C terminus and six tetratricopeptide repeat (TPR) domains at the N terminus [43] (Fig. 1).

JMJD3 catalyzes the transition from a repressive status (H3K27me3) to active status (H3K27me1) [44]. JMJD3 in a demethylase-dependent or independent manner can regulate gene transcription [45]. Polycomb repressive complex 2 (PRC2, composed of the enzyme EZH2, SUZ12, and EED) is a transcriptional repressor that interacts with PRC1 and adds methyl groups to histone H3K27. JMJD3, which opposes the enzymatic activity of the PRC2, regulates the expression of specific genes. JMJD3 as a transcription factor can interact with co-activators and regulate the transcription of target genes.

JMJD3 function in embryonic stem cells

JMJD3 plays a critical role in undifferentiated ESCs and ESC-derived cell gene expressions [60]. GSK-J4 by suppressing the enzymatic activity of JMJD3 triggers cell cycle arrest, DNA damage, and cell death in ESCs-derived cells but not in undifferentiated ESCs [60].

The expression profile of JMJD3 suggests that it may contribute to the regulation of ectoderm, mesoderm, and endoderm differentiation in murine and human ESCs [11, 17, 18] (Fig. 2).

- Differentiation of ESCs into ectoderm lineage

During differentiation of ESC to the neuronal lineage, JMJD3 can modulate the expression of key markers of neurogenesis (Pax6, Nestin, and Sox1) and enhance neural commitment [61].

Vitamin C is a critical micronutrient that improves the rate of ESC proliferation and the efficiency of iPSC formation [62]. In mouse ESC differentiation, vitamin C can impact JMJD3 and induce a pluripotent state [63], but during the differentiation of dopamine neurons in the fetal midbrain, vitamin C upregulates JMJD3 and decreases the H3K27m3 of dopamine phenotypic to facilitate dopamine neuron differentiation [64].
Fig. 1 (See legend on previous page.)
Fig. 2  JMJD3 function in pluripotent stem cells. JMJD3 plays a critical role in the differentiation of ESCs and iPSCs. The expression profile of JMJD3 suggests that it may contribute to the regulation of ectoderm, mesoderm, and endoderm differentiation in murine and human ESCs. JMJD3 as an epigenetic barrier is thought to increase during the reprogramming of differentiated cells into iPSCs.
**JMJD3 function in multipotent stem cells**

- Neural stem cells

It has been reported that JMJD3 interacts with the activated SMAD3 and enhances the differentiation of neural stem cells (NSCs) [76]. JMJD3 is required to interact with neural promoters, regulate neurogenic gene expression, and activate neurogenesis from the adult subventricular zone (SVZ)-derived NSCs [77]. Following differentiation of NSCs to neurons, SMRT (NCoR2, nuclear receptor co-repressor 2) inhibits JMJD3 and maintains the NSCs state [78]. STAT3 as an important component of the LIF signaling pathway is necessary for stem cell self-renewal [79, 80]. STAT3 binds to the JMJD3 promoter, prevents the demethylase activity of JMJD3, and suppresses the activity of differentiation-specific genes [81–83]. It has been shown that inhibition of STAT3 in glioblastoma stem cells (GBM-SC) can promote the levels of histone H3K27 demethylation and the expression of neural-specific genes, such as FGF21, GDF15, and Myt1 [52]. The p53 tumor suppressor has a key role in mouse neurogenesis [84, 85]. In response to differentiation inducers, the recruitment of JMJD3 to p53 responsive elements is increased [86]. During mouse NSCs differentiation, JMJD3 is thought to act as a tumor suppressor and increase the expression of the INK4a/ARF (or CDKN2a) locus, and then stabilize the nuclear distribution of P53 [87].

- Osteogenic stem cells

JMJD3 by removing H3K27me3 plays an important role in the osteogenic commitment of MSCs [88]. JMJD3 appears to induce osteoblast differentiation by stimulating transcription factors Runx2 and Osterix and control the expressions of bone-related genes [44, 89]. Ras-association domain family 5 (RASSF5) or novel Ras effector 1 (NORE1) is a pro-apoptotic protein that regulates a variety of key biological processes [90, 91]. JMJD3 was reported to reduce the expression of RASSF5 and suppress tumor necrosis factor-alpha (TNF-α)-induced osteoblast apoptosis [92].

MicroRNA-99a by targeting JMJD3 is involved in osteogenic differentiation of bone MSCs [93, 94]. In contrast, MIR146A is a negative regulator of JMJD3 and RUNX2 that reduces MSCs capacity to differentiate into osteoblasts [95]. The PLZF transcription factor was previously shown to play an essential role in the osteogenic fate of human MSCs. At the pre-osteoblast stage of differentiation (osteoblast commitment of progenitor cells), JMJD3 enhances the expression of PLZF and controls osteoblast differentiation in MSCs [96]. Nuclear factor–activated

**The role of JMJD3 in reprogramming**

JMJD3 as an epigenetic barrier is thought to be increased during the reprogramming of differentiated cells into iPSCs [72] (Fig. 2). It was recently reported that JMJD3 interacts with KLF4 and decreases H3K27me3 in pluripotency genes [34]. A recent study has shown that the Jmjd3-PHF20 axis plays a key role in the reprogramming of somatic cells [33]. PHF20 (plant homeodomain finger protein 20 or glioma-expressed antigen 2) is a critical epigenetic regulator that enhances reprogramming and stemness through activation of Oct4 and Sox2 [73]. JMJD3 by recruiting an E3 ligase Trim26 causes the ubiquitination and degradation of PHF20 [33, 74]. JMJD3 through its H3K27me2/3 demethylase activity enhances the expression of Ink4a/Arf and P21. Thus, a decrease in PHF20 leads to reduce endogenous Oct4 expression, cell proliferation, and the outcome of reprogramming [33]. JMJD3 by removing the H3K27me3 mark from the hepatic transcription factors (HTFs) promoter is participate in the reprogramming of bone marrow progenitor cells (BMPCs) to hepatic cells. In contrast, GSK-J4 can effectively repress the activity of JMJD3 and the loss of the H3K27me3 chromatin mark in BMPCs [75].

**Differential of ESCs into endoderm lineage**

NODAL is the central transcription factor of TGF-β signaling and a target for repression by Polycomb proteins and accumulation of H3K27me3 [70]. SMAD2/3 proteins that transduce signals from TGF-β signaling are capable of recruiting JMJD3 to remove the H3K27me3 repressive mark on the NODAL promoter and facilitate human ESCs differentiation into endoderm [71].
T cells c1 (NFATc1) is a key transcription factor that induces osteoclast differentiation in response to receptor activator of nuclear factor-κB ligand (RANKL) [66]. JMJD3 has been shown to remove the inhibitory H3K27me3 marker on the Nfatc1 gene and regulate RANKL-mediated osteoclast differentiation [97]. The inhibition of JMJD3 activity by GSK-J4 could be used as a non-invasive treatment for preventing the prefusion of cranial sutures in a patient with excessive osteogenic differentiation of MSCs [98].

- Dental pulp-derived MSCs

JMJD3 by removing H3K27me3 from the promoters of osteogenic genes improves the odontogenic differentiation in dental pulp-derived MSCs [44, 99]. Ethanol (EtOH) can suppress JMJD3 and alter DNA methylation. EtOH-induced DNA methylation influences odontogenic differentiation and reduces mineralization [100]. Insulin-like growth factor binding protein 5 (IGFBP5) is a multifunctional protein with anti-inflammatory potential that promotes osteogenic differentiation in dental pulp-derived MSCs [101, 102]. A recent study showed JMJD3 through the removal of H3K27me3 at the promoter of IGFBP5 mediated periodontal tissue regeneration [101].

- Hematopoietic stem cells

JMJD3 is necessary for the self-renewal properties of hematopoietic stem cells (HSCs) [103]. Unlike KDM6A, which is frequently mutated in hematopoietic disorders, JMJD3 is necessary for HSC self-renewal in response to stress conditions [104, 105]. The adaptor-related protein complex 1 (AP-1) transcription factors such as Fos and JunB are crucial for interleukin (IL)-17-producing T helper (Th17) cell development [106]. JMJD3 was found to modulate the MAPK pathway, suppress the expression of AP-1, and support leukemia initiation and maintenance [107]. Hence, targeted inhibition of JMJD3 led to increasing HSCs differentiation [74].

These studies suggest that JMJD3 might be a feasible and effective target for cell fate regulation of multipotent stem cells.

**Conclusion**

In this review, we summarize the roles of JMJD3 in pluripotency, reprogramming, and differentiation. JMJD3 has been found in several biological processes, including cell proliferation, differentiation, invasion, apoptosis, signaling regulatory pathways. Direct manipulation of epigenomes may be a suitable method for generating desired cell types from pluripotent or multipotent stem cells. Although JMJD3 via epigenetic modifications targets several signaling pathways, off-target effects could lead to minimize the applications of this enzyme in cancer. For example, JMJD3 by promoting cyclin D1 transcription is involved in the development of cancer cells [108]. Also, JMJD3 can impact other histone modifiers and alter chromatin structure, activate the expression of oncogenes, and trigger the development of many types of human diseases [108]. Thus, further studies are required to determine the downstream targets of JMJD3 in pluripotent and multipotent stem cells.

**Abbreviations**

AP-1: Adaptor related protein complex 1; AT: Adipose tissues; BM: Bone marrow; BSCB: Blood-spinal cord barrier; DP: Dental pulp; ESCs: Embryonic stem cells; HSCs: Hematopoietic stem cells; HTFs: Hepatic transcription factors; H3K27me3: Trimethylation of histone H3 on lysine 27; ICM: Inner cell mass; IGFBP5: Insulin-like growth factor binding protein 5; iPSCs: Induced pluripotent stem cells; JMJD3: Jumonji domain-containing protein-3; KDM6B: Lysine-specific demethylase 6B; LSD1: Lysine-specific demethylase 1; MSCs: Mesenchymal stem cells; NCoR2: Nuclear receptor co-repressor 2; NORE1: Novel Ras effector 1; NFATc1: Nuclear factor–activated T cells c1; PHF20: Plant homeodomain finger protein 20; Pol II: Polymerase II; PRC2: Polycomb repressive complex 2; PSCs: Pluripotent stem cells; RASSF5: Ras-association domain family 5; SCI: Spinal cord injury; SESN2: Sestrin2; SVZ: Subventricular zone; T-ALL: T-cell acute lymphoblastic leukemia; TFs: Transcription factors; TNF-α: Tumor necrosis factor-alpha; UCB: Umbilical cord blood.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12964-021-00753-8.

**Acknowledgements**

The study was supported by the National Natural Science Foundation of China (Grant No. 31260634) and the Science and Technology Program of Jishou University (Grant No. DNGC2010).

**Authors’ contributions**

YD and YY have made substantial contributions to the writing of the manuscript. XG has made a substantial contribution to the design of the Figures and writing of the manuscript. ZC and JC contributed to the revision of the manuscript. MT and MF has made a substantial contribution to the final revision of the manuscript. All authors have approved the submitted version of the article and have agreed to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work. All authors read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no conflict of interest.
Author details

1 School of Medicine, Jishou University, Jishou 416000, China. 2 Key Laboratory of Human Forest Products and Chemical Industry Engineering, Jishou University, Zhangjiajie 427000, China. 3 Fermentation, Interfertility and Penetatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Received: 10 April 2021  Accepted: 21 May 2021
Published online: 03 July 2021

References

1. Gibney E, Nolan C. Epigenetics and gene expression. Heredity. 2010;105:4–13.
2. Miller JL, Grant PA. The role of DNA methylation and histone modifications in transcriptional regulation in humans. Subcell Biochem. 2013;61:289–317.
3. Chen Y, Ren B, Yang J, Wang H, Yang G, Xu R, You L, Zhao Y. The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduct Target Ther. 2020;5:143.
4. Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol. 2016;9:49–49.
5. Wiles ET, Selker EU. H3K27 methylation: a promiscuous repressive chromatin mark. Curr Opin Genet Dev. 2017;43:31–7.
6. Akter A, Takahashi S, Deng W, Shea DJ, Miyaji N, Osabe K, Nishida N, Suzuki Y, Hellwell CA, Seki M, Peacock WJ, Dennis ES, Fujimoto R. The histone modification H3 lysine 27 tri-methylation has conserved gene regulatory roles in the triplicated genome of Brassica rapa. DNA Res. 2019;26:433–43.
7. Sen GL, Webster DE, Barragan DI, Chang HY, Khavari PA. Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3. Genes Dev. 2008;22:1865–70.
8. Petruk S, Cai J, Sussman R, Sun G, Kovermann SK, Mariani SA, Calabretta B, McMahon SB, Brock HW, Iacovitti L, Mazo A. Delayed accumulation of H3K27me3 on nascent DNA is essential for recruitment of transcription factors at early stages of stem cell differentiation. Mol Cell. 2017;66:247-257.e245.
9. Canovas S, Cibelli JB, Ross PJ. Junomji domain-containing protein 3 regulates histone 3 lysine 27 methylation during bovine preimplantation development. Proc Natl Acad Sci. 2012;109:2400–5.
10. Yin X, Yang S, Zhang M, Yue Y. The role and prospect of JMJD3 in stem cells and cancer. Biomed Pharmacother. 2019;118:109384.
11. Srinageshwar B, Matti P, Dunbar GL, Rossignol J. Role of epigenetics in stem cell proliferation and differentiation: implications for treating neurodegenerative diseases. Int J Mol Sci. 2016;17:1799.
12. Burchfield JS, Li Q, Wang HY, Wang R-F. JMJD3 as an epigenetic regulator in development and disease. Int J Biochem Cell Biol. 2015;67:148–57.
13. Burgold T, Voituron N, Cagavana M, Tripathi Prem P, Menuet C, Tusi Betsabeh K, Spreafico F, Bévegut M, Gestreau C, Buontempo S, Simeone A, Kruidener L, Natoli G, Casola S, Hilaire G, Testa G. The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival. Cell Rep. 2012;2:1244–58.
14. Yu X-X, Qiu W-L, Yang L, Li L-C, Zhang Y-W, Xu C-R. Dynamics of chromatin marks and the role of JMJD3 during pancreatic endocrine cell fate commitment. Development. 2018;145:dev163162.
15. Iida A, Iwagaawa T, Kuribayashi H, Satoh S, Mochizuki Y, Baba Y, Nakauchi H, Furukawa T, Koseki H, Murakami A, Watanabe S. Histone demethylase Jmd3 is required for the development of subsets of retinal bipolar cells. Proc Natl Acad Sci U S A. 2014;111:3751–5.
16. Bergmann C, Brandt A, Merlevede B, Hallenberger L, Dees C, Wohlfahrt T, Potter S, Zhang Y, Chen C-W, Mallano T, Li J, Kangwira R, Kreuter A, Pantelaki I, Bozec A, Abraham D, Rieker R, Ramsing A, Distler O, Schett G, Distler JMH. The histone demethylase Junomji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis. 2018;77:150–8.
17. Shan Y, Zhang Y, Zhao Y, Wang T, Zhang J, Yao J, Ma N, Liang Z, Huang W, Huang K, Zhang T, Su Z, Chen Q, Zhu Y, Wu C, Zhou T, Sun W, Wei Y, Zhang C, Li C, Su S, Liao B, Zhong M, Zhong X, Nie J, Pei D, Pan G. JMJD3 and UTX determine fidelity and lineage specification of human neural progenitor cells. Nat Commun. 2020;11:582.
18. Han JW, Yoon Y-S. Epigenetic landscape of pluripotent stem cells. Antioxid Redox Signal. 2012;17:205–23.
19. Farzaneh M, Derakhshan Z, Hallelajad E, Sanjari NH, Nejabatdoust A, Koseki H. Suppression of TGF-β and ERK signaling pathways as a new strategy to provide rodent and non-rodent pluripotent stem cells. Curr Stem Cell Res Ther. 2019;14:466–73.
20. Kolagar TA, Farzaneh M, Nikkar N, Kosehnum SE. Human pluripotent stem cells in neurodegenerative diseases: potentials, advances and limitations. Curr Stem Cell Res Ther. 2020;15:102–10.
21. Pan B, Fan G. Stem cell-based treatment of kidney diseases. Exp Biol Med. 2020;15353702209501.
22. Paredes-Redondo A, Lin YY. Human induced pluripotent stem cells: challenges and opportunities in developing new therapies for muscular dystrophies. el5. 2019;1:1–10.
23. Bai X. Stem cell-based disease modeling and cell therapy. Multidisciplinary Digital Publishing Institute. 2020.
24. Borovjak T, Loso R, Bertone P, Smith A, Nichols J. The ability of inner-cell mass cells to self-renew as embryonic stem cells is acquired following epiblast specification. Nat Cell Biol. 2014;16:516–28.
25. Zhao N, Sheng M, Wang X, Li Y, Farzaneh M. Differentiation of human induced pluripotent stem cells into male germ cells. Curr Stem Cell Res Ther. 2020;17:1–8.
26. Farzaneh M, Kosehnum S, Mozdziak P. Concise review: avian multipotent stem cells as a novel tool for investigating cell-based therapies. J Dairy Vet Anim Res. 2017;7:00125.
27. Javan MR, Kosehnum S, Mozdziak P. New insights into implementation of mesenchymal stem cells in cancer therapy: prospects for anti-angiogenesis treatment. Front Oncol. 2019;9:9840.
28. Maiti P, Dunbar GL, Rossignol J. Role of epigenetics in stem cell: an epigenetic perspective. Cell Res. 2013;23:49–69.
29. Rosas-Dunju CA, Canul-Chan M, Rojas-Herrera RA, de-la-Peña C, Nic Can Gl. Stem cells from dental pulp: what epigenetics can do with your tooth. Front Physiol. 2017;8:999–999.
30. Ohtani K, Zhao C, Dobreva G, Manavski Y, Cluge B, Braun T, Rieger MA, Zeiher AM, Dimmeler S. Jmj3 controls mesodermal and cardiovascular differentiation of embryonic stem cells. Circ Res. 2013;113:856–62.
31. Liu M, Guo J, Wu B, Zhou Y, Wu M, Farzaneh M, Kosehnum SE. Mesenchymal stem cell-mediated mitochondrial transfer: a therapeutic approach for ischemic stroke. Transl Stroke Res. 2020;12(2):212–29.
32. Lu M, Guo J, Wu B, Zhou Y, Wu M, Farzaneh M, Kosehnum SE. Mesenchymal stem cell-mediated mitochondrial transfer: a therapeutic approach for ischemic stroke. Transl Stroke Res. 2020;12(2):1307–50.
33. Zhao W, Li Q, Ayers S, Gu Y, Shi Z, Zhu Q, Chen Y, Wang HY, Wang R-F. Jmd3 inhibits reprogramming by upregulating expression of INK4a/Rarf and targeting PHF20 for ubiquitination. Cell. 2013;152:1037–50.
34. Huang Y, Zhang H, Wang L, Tang C, Qin X, Wu X, Pan M, Tang Y, Zhang Z, Babarinde IA, Lin R, Ji G, Lai Y, Xu X, Su J, Wen X, Satoh T, Ahmed T, Malik V, Ward C, Volpe G, Guo L, Chen J, Sun L, Li Y, Huang X, Rao X, Gao F, Liu B, Zheng H, Jauch R, Lai P, Gan C, Chen J, Testa G, Akira S, Hu J, Pei D, Hutchins AP, Esteban MA, Qin B. JMJD3 acts in tandem with KLF4 to facilitate reprogramming to pluripotency. Nat Commun. 2020;11:5061.
35. Wilson C, Krieg AJ. KDM4B: a nail for every hammer? Genes (Basel). 2019;10:134.
36. D’Oro A, Tian Q-W, Davidoff AM, Yang J. Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther. 2016;1:34.
37. Labbé RM, Holovaty A, Yang Z-Q. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. Am J Transl Res. 2014;6:1.
41. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7:175–27.

42. Gang Xiao Z, Shen J, Zhang L, Li LF, Xing Li M, Hu W, Jie Li Z, Hin Cho C. The roles of histone demethylase UTX and JMJD3 (KDM6B) in cancers: current progress and future perspectives. Curr Med Chem. 2016;23:3687–96.

43. Tran N, Broun A, Ge K. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer. Mol Cell Biol. 2020;40.e00341.

44. Yang D, Yu B, Sun H, Qiu L. The roles of histone demethylase JMJD3 in osteoblast differentiation and apoptosis. J Clin Med. 2017;6:24.

45. Zhang X, Liu L, Yuan X, Wei Y, Wei X. JMJD3 in the regulation of human diseases. Protein Cell. 2019;10(12):864–82.

46. Kasinath V, Poepsei S, Nogales E. Recent structural insights into Polycomb repressive complex 2 regulation and substrate binding. Biochemistry. 2018;58:346–54.

47. Jiao H, Xie Y, Li Z. Current understanding of plant Polycomb group proteins and the repressive histone H3 Lysine 27 trimethylation. Biochem Soc Trans. 2020;48:697–706.

48. Iwagawa T, Honda H, Watanabe S. JMJD3 plays pivotal roles in the proper development of early-born retinal lineages: amacrine, horizontal, and retinal ganglion cells. Invest Ophthalmol Vis Sci. 2020;61:43–43.

49. Argaud D, Boulanger M-C, Chignon A, Mkannez G, Mathieu P. Enhancer-mediated enrichment of interacting JMJD3–DDX21 to ENPP2 locus prevents locus formation and promotes transcription. Nucleic Acids Res. 2019;47:8424–38.

50. Chen S, Ma J, Wu F, Xiong L-J, Ma H, Xu W, Lv R, Li X, Villen J, Gygi SP. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev. 2012;26:1364–75.

51. Xun J, Wang D, Sheng L, Gong J, Gao R, Du L, Chang A, Song X, Xiang R, Tan X. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity. Oncotarget. 2017;8:21918.

52. Sherry-Lynes MM, Sengupta S, Kulkarni S, Cochran BH. Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by transcription factors. PLoS ONE. 2017;12:e0177475.

53. Qin M, Han F, Wu J, Gao F-X, Li Y, Yan D-X, He X-M, Long Y, Tang X-p, Ren D-J. KDM6B promotes ESCC cell proliferation and metastasis by facilitating C/EBPβ transcription. 2020.

54. Li Q, Zou J, Wang J, Ding X, Chepelev J, Zhou X, Zhao W, Wei G, Cui J, Zhao K. Critical role of histone demethylase JMJD3 in the regulation of CD4+ T-cell differentiation. Nat Commun. 2014;5:1–15.

55. Wang P, Lan R, Guo Z, Cai S, Wang J, Wang Q, Li Z, Li Z, Wang Q, Li J. Histone demethylase JMJD3 mediated doxorubicin-induced cardiomyopathy by suppressing SENS2 expression. Front Cell Dev Biol. 2020;8:1037.

56. Park CS, Lee JY, Choi HY, Lee K, Heo Y, Ju BG, Choo H-YP, Yune TY. Gallic acid attenuates blood-spinal cord barrier disruption by inhibiting Jmjd3 expression and activation after spinal cord injury. Neurobiol Dis. 2019;12:9385–93.

57. Hofstetter C, Kampka JW, Huppertz S, Weber H, Schlosser A, Müller AM, Becker M. Inhibition of KDM6 activity during murine ESC differentiation induces DNA damage. J Cell Sci. 2016;129:788–803.

58. Burgold T, Spreafico F, De Santa F, Totaro MG, Prosperini E, Natoli G, Testa R. The Jmjd3–DDX21 interaction controls the repressor activity in AML. Nat Commun. 2018;9:1–15.

59. He XB, Kim M, Kim SY, Yi SH, Rhey YH, Kim T, Lee EH, Park CH, Dixit S, Harrison FE. Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET 1 and JMJD3-dependent epigenetic control manner. Stem Cells. 2015;33:1320–32.

60. Yang D, Li Y, Guo C, Lu Q, Wang W, Jia Z, Chen P, Ma K, Reinberg D, Zhou C. JmjC and JMJD3 synergistically control cardiac differentiation of embryonic stem cells. Nucleic Acids Res. 2014;64:6741–55.

61. Kim JH, Kim N. Regulation of NfATc1 in osteoclast differentiation. J Bone Metab. 2014;21:233–41.

62. Ziegler N, Bader E, Epanchintsev A, Margerie D, Knaus A, Schmoll D. AMPKβ1 and AMPKβ2 define an isoform-specific gene signature in human pluripotent stem cells, differentially mediating cardiac lineage specification. J Biol Chem. 2020;295:17659–71.

63. Wang W, Jiang Z. Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway. Cell Res. 2013;23:122–30.

64. Akiyama T, Wakabayashi S, Soma A, Sato S, Nakataya Y, Oda M, Murakami M, Sakota M, Chikazawa-Nohtomi N, Ko SB. Transient ectopic expression of the histone demethylase JMJD3 accelerates the differentiation of human pluripotent stem cells. Development. 2016;143:3674–85.

65. Dahle Ø, Kumar A, Kuehn MR. Nodal signaling recruits the histone demethylase Jmjd3 to counteract polycomb-mediated repression at target genes. Science signaling. 2010;3:ra48.

66. Kim SW, Yoon S-J, Cheung E, Oyolu C, Willis AE, Gupta R, Baker C. Chromatin and transcriptional signatures for Nodal signaling during endoderm formation in hESCs. Dev Biol. 2011;357:492–504.

67. Akiyama T, Wakabayashi S, Soma A, Sato S, Nakataya Y, Oda M, Murakami M, Sakota M, Chikazawa-Nohtomi N, Ko SB, Ko MSH. Transient ectopic expression of the histone demethylase JMJD3 accelerates the differentiation of human pluripotent stem cells. Development. 2016;143:3674–85.

68. Long W, Zhao W, Ning B, Huang J, Chiu J, Li L, Ma Q, Xing C, Wang HY, Liu Q, Wang R-F. PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4. J Mol Cell Biol. 2018;10:147–60.

69. Niemitz E. Jmjd3, PHF20 and reprogramming. Nat Genet. 2013;45:477–477.

70. Estarás C, Akizu N, García A, Beltrán S, de la Cruz X, Martínez-Balbás MA. JmjC domain-containing proteins and histone demethylation. Stem Cells. 2015;33:1320–32.

71. Ziegler N, Bader E, Epanchintsev A, Margerie D, Kannt A, Schmoll D. AMPKβ1 and AMPKβ2 define an isoform-specific gene signature in human pluripotent stem cells, differentially mediating cardiac lineage specification. J Biol Chem. 2020;295:17659–71.

72. Argaud D, Boulanger M-C, Chignon A, Mkannez G, Mathieu P. Enhancer-mediated enrichment of interacting JMJD3–DDX21 to ENPP2 locus prevents locus formation and promotes transcription. Nucleic Acids Res. 2019;47:8424–38.
84. Mendrysa SM, Ghassemifar S, Malek R. p53 in the CNS: perspectives on development, stem cells, and cancer. Genes Cancer. 2011;2:431–42.

85. Niklison-Chirou MV, Agostini M, Amelia L, Melino G. Regulation of adult neurogenesis in mammalian brain. Int J Mol Sci. 2020;21:4869.

86. Williams K, Christensen J, Rappaport J, Nielsen AL, Johansen JV, Helin K. The histone lysine demethylase JMJD3/DKDM6B is recruited to p53 bound promoters and enhancer elements in a p53 dependent manner. PLoS ONE. 2014;9:e96545.

87. Solà S, Xavier JM, Santos DM, Aranha MM, Morgado AL, Jepsen K, Rodrigues CM. p53 interaction with JMJ3/D3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS ONE. 2011;6:e18421.

88. Ye L, Fan Z, Yu B, Chang J, Al Hezami K, Zhou X, Park N-H, Wang C-Y. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell. 2012;11:50–61.

89. Yang D, Okamura H, Nakashima Y, Haneji T. Histone demethylase JmjD3 regulates osteoblast differentiation via transcription factors Runx2 and osterix. J Biol Chem. 2013;288:33530–41.

90. Park J, Kang SI, Lee S-Y, Zhang XF, Kim MS, Beers LF, Lim D-S, Avruch J, Kim H-S, Lee SB. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem. 2010;285:35029–38.

91. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776:58–85.

92. Sun H-Y, Yang D, Mi J, Yu Y-Q, Qiu L-H. Histone demethylase Jmjd3 modulates osteoblast apoptosis induced by tumor necrosis factor-alpha through directly targeting RASSF5. Connect Tissue Res. 2020;61:517–25.

93. Tang Y, Zhang L, Tu T, Li Y, Murray D, Tu Q, Chen JJ. MicroRNA-99a is a novel regulator of KDM6B-mediated osteogenic differentiation of BMSCs. J Cell Mol Med. 2018;22:2162–76.

94. Moura SR, Bras JP, Freitas J, Osório H, Barbosa MA, Santos SG, Almeida ML. miR-99a in bone homeostasis: regulating osteogenic lineage commitment and osteoclast differentiation. Bone. 2020;134:115303.

95. Huszar JM, Payne CJ. MIR146A inhibits JmjD3 expression and osteogenic differentiation in human mesenchymal stem cells. FEBS Lett. 2014;588:1850–6.

96. Singh SA, Lerdrup M, Gomes A-LR, van de Werken HJ, Johansen JV, Andersson R, Sandelin A, Helin K, Hansen K. PLZF targets developmental enhancers for activation during osteogenic differentiation of human mesenchymal stem cells. Elife. 2019;8:40364.

97. Yasui T, Hirose J, Tsutsumi S, Nakamura K, Aburatani H, Tanaka S. Epigenetic regulation of JmjD3 is the histone demethylation of Nfatc1. J Bone Miner Res. 2011;26:2665–71.

98. Pribadi C, Camp E, Cakouros D, Anderson P, Glackin C, Gronthos S. Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre–Chotzen syndrome. Stem Cell Res Ther. 2020;11:529.

99. Xu J, Yu B, Hong C, Wang C-Y. KDM6B epigenetically regulates odontogenic differentiation of dental mesenchymal stem cells. Int J Oral Sci. 2013;5:200–5.

100. Hoang M, Kim Ji, Kim Y, Tong E, Trammell B, Liu Y, Shi S, Lee C-R, Hong C, Wang C-Y. Alcohol-induced suppression of KDM6B dysregulates the mineralization potential in dental pulp stem cells. Stem cell research. 2016;17:111–21.

101. Liu D, Wang Y, Jia Z, Wang L, Wang J, Yang D, Song J, Wang S, Fan Z. Demethylation of IGFBPs by histone demethylase KDM6B promotes mesenchymal stem cell-mediated periodontal tissue regeneration by enhancing osteogenic differentiation and anti-inflammation potential. Stem Cells. 2015;33:2523–36.

102. Wang Y, Jia Z, Diao S, Lin X, Liang J, Wang L, Dong R, Liu D, Fan Z. Igfbp5 enhances osteogenic differentiation potential of periodontal ligament stem cells and Wharton’s jelly umbilical cord stem cells, via the JNK and MEK/Erk signalling pathways. Cell Prolif. 2016;49:618–27.

103. Sui B-D, Zheng C-X, Li M, Jin Y, Hu C-H. Epigenetic regulation of mesenchymal stem cell homeostasis. Trends Cell Biol. 2020;30:97–116.

104. Mallaney C. Kdm6b is required for self-renewal of normal and leukemic mouse stem cells under proliferative stress. 2018.

105. Wei Y, Zheng H, Jia Y, Yao N, Jiang S, Colla S, Bueso-Ramos CE, Khoury JD, Bohannan ZS, Garcia-Manero G. Overexpression of KDM6B, an epigenetic and innate immune regulator, results in hematopoietic alterations of mice including changes in hematopoietic stem cells. American Society of Hematology Washington, 2016.

106. Yamazaki S, Tanaka Y, Araki H, Kohda A, Sanematsu F, Arasaki T, Duan X, Wei Y, Hirose J, Tsutsumi S, Nakamura K, Aburatani H, Tanaka S. Epigenetic regulation of mesenchymal stem cell-mediated periodontal tissue regeneration by demethylating H3K27me3 at cyclin D1 promoter. Cell Death Dis. 2021;12:2.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.